Merck KGaA Raises 2026 Outlook After Q3 Sales Growth
Merck KGaA reported third-quarter net profit down 49.9 percent to €450 million, while sales rose 5.8 percent to €5.627 billion and EBITDA pre increased 0.8 percent to €1.682 billion. The company raised its fiscal 2026 outlook to net sales of €21.5 billion to €21.9 billion and EBITDA pre of €6.2 billion to €6.4 billion. The updated outlook includes the Bio-Techne acquisition, which is expected to close in December 2026.
Why it matters
The higher guidance raises Merck KGaA’s stated fiscal 2026 sales and EBITDA pre ranges, changing the company’s earnings outlook for investors. The Bio-Techne transaction is included in the updated forecast as a portfolio effect in the Life Science sector.
Key facts
- 1Third-quarter net profit fell 49.9 percent to €450 million from €898 million in the prior-year period. rttnews.com
- 2Third-quarter net sales increased 5.8 percent to €5.627 billion, while organic net sales growth was 5.1 percent. rttnews.com
- 3Third-quarter EBITDA pre rose 0.8 percent to €1.682 billion, while organic EBITDA pre growth was approximately 0.4 percent. rttnews.com
- 4Merck KGaA now expects fiscal 2026 net sales of €21.5 billion to €21.9 billion and EBITDA pre of €6.2 billion to €6.4 billion, compared with prior ranges of €21.0 billion to €21.8 billion and €5.9 billion to €6.3 billion. rttnews.com
- 5Merck plans to acquire Bio-Techne for $11.3B, with the transaction expected to close in December 2026. grafa.com
Open questions
- reports an EBITDA pre margin of 18.5%, while reports an EBITDA pre margin of 29.9%; the materials do not reconcile the difference.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.